학술논문
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
Document Type
Article
Author
Source
In ESMO Open December 2023 8(6)
Subject
Language
ISSN
2059-7029